Cognitive · Reference
Can You Take PE-22-28 With Tirzepatide or Semaglutide?
This page covers what each medication does, where they meet, the GLP-1 effects worth ruling out first, blood sugar, psychiatric medication, and how the two schedules fit.

Treatments mentioned
PE-22-28 can be prescribed alongside tirzepatide or semaglutide after a physician reviews your intake: PE-22-28 is described as blocking the TREK-1 potassium channel in neurons, tirzepatide acts on appetite and gastric emptying, and no interaction between them is described. Nobody has studied the pairing, and PE-22-28 has no human trials of any kind, so "no interaction described" means none has been looked for. Two points matter most. Some GLP-1 side effects, such as fatigue, dizziness and low blood sugar, can feel like low mood or anxiety and should be reported before anything is added. And cell work described PE-22-28's parent peptide increasing insulin secretion, which puts blood sugar on the watch list for anyone on a GLP-1 who also takes insulin or a sulfonylurea. Everything on this page applies to semaglutide the same way.
If you are in crisis or thinking about harming yourself, call or text 988 in the US, or call 911, now.
This page covers what each medication does, where they meet, the GLP-1 effects worth ruling out first, blood sugar, psychiatric medication, and how the two schedules fit.
Can You Take PE-22-28 With Tirzepatide or Semaglutide?
The short answer
| Question | Answer |
|---|---|
| Can PE-22-28 and tirzepatide be taken together? | Yes, after a physician reviews your intake |
| Is there a known interaction? | None is described; PE-22-28 has no established interaction list |
| Has the combination been studied? | No; PE-22-28 has not been studied in people at all |
| Is PE-22-28 a treatment for low mood on a GLP-1? | No study has tested that; report the mood change first |
| What overlaps? | Early tiredness, injection-site reactions, and the blood sugar question |
| On an antidepressant or other serotonergic drug? | That treatment comes first; tell your prescribers |
| Same answer for semaglutide? | Yes |
The medications this page covers:
| Product | What is in it | Typical printed directions | Price |
|---|---|---|---|
| PE-22-28 | 5 mL multi-dose vial, 2 mg/mL (10 mg per vial) | 0.25 mL (25 units) under the skin once daily, Monday through Friday | $219/mo |
| Tirzepatide | Dose-specific 2 mL vials, 2.5 mg to 15 mg weekly | 0.50 mL (50 units) once weekly | From $159/mo |
| Semaglutide | Dose-specific vials at six strengths | Printed on the vial | From $99/mo |
Every price is all-in, covering medication, physician review, refill management and shipping, with no membership fee. GLP-1 prices are "from" prices because they are priced by dose. Compounded medications are not FDA approved.
Can You Take PE-22-28 With Tirzepatide or Semaglutide?
Two medications doing unrelated jobs
PE-22-28
PE-22-28 is a seven-amino-acid fragment of the sortilin propeptide, a piece clipped off when the body makes the sortilin receptor. It blocks TREK-1, a background potassium channel that helps set how easily a neuron fires. In rodents, blocking TREK-1 on serotonin neurons was associated with increased firing and antidepressant-like behaviour after a four-day course. There are no human trials. It is not described as acting on appetite, digestion or weight. See what is PE-22-28.
Tirzepatide
Tirzepatide activates the GIP and GLP-1 receptors. It acts on appetite centres in the brain, slows gastric emptying and changes insulin and glucagon signalling, and it is dosed once a week. See what is tirzepatide.
| PE-22-28 | Tirzepatide | |
|---|---|---|
| Described target | TREK-1 potassium channel in neurons | GIP and GLP-1 receptors |
| Described around | Mood-related behaviour in rodents | Appetite, gastric emptying, insulin and glucagon |
| Acts on appetite? | Not described to | Yes, its main action |
| Human evidence | None | Large randomised trials of the approved product |
| Schedule | Weekdays | Once weekly |
Can You Take PE-22-28 With Tirzepatide or Semaglutide?
Rule out the GLP-1 first
People sometimes ask about PE-22-28 because their mood dipped after starting a GLP-1. Pepti's references do not list anxiety or depression among tirzepatide's side effects. For semaglutide, a large 2024 Nature Medicine cohort of 240,618 people reported lower rates of new suicidal ideation than on other weight-management drugs, and the suicidal-behavior warning on the approved semaglutide weight-management label was removed in February 2026. But several physical GLP-1 effects can feel like low mood or anxiety.
| What you feel | A possible GLP-1 cause | What to do |
|---|---|---|
| Tiredness, low energy, a flat feeling | Eating and drinking too little; fatigue 5 to 7% on tirzepatide against 3% on placebo | Report it if it persists |
| Shakiness, sweating, confusion | Low blood sugar, mainly with insulin or a sulfonylurea | Treat it, then report it |
| Dizziness, light-headedness on standing | Low blood pressure or dehydration | Drink enough; same-day call if you cannot keep fluids down |
| A knotted, queasy stomach | Slower gastric emptying | Smaller meals; report it |
Describe exactly what you feel and when, so your care team can tell these apart. Adding PE-22-28 to treat what is actually under-eating or low blood sugar would miss the cause, and PE-22-28 has never been tested for mood in a person. More is in GLP-1 anxiety and depression.
Can You Take PE-22-28 With Tirzepatide or Semaglutide?
Blood sugar: the specific question for this pairing
Cell work described the parent peptide of PE-22-28 increasing insulin secretion from pancreatic beta cells (Journal of Diabetes Research, 2016). Nobody has measured that in people taking PE-22-28. Tirzepatide on its own rarely causes low blood sugar, but the risk rises with insulin or a sulfonylurea.
| Your situation | What it means |
|---|---|
| No diabetes, no glucose-lowering medication | No specific signal; report shakiness or sweating if it happens |
| Type 2 diabetes on tirzepatide alone | List it; your physician reviews the cell-work point |
| On insulin or a sulfonylurea as well | Low blood sugar is the main thing to watch; your physician reviews all three |
Know the signs of low blood sugar: shakiness, sweating, a fast heartbeat, confusion. Treat it first, then report it. Never change an insulin or sulfonylurea dose on your own.
Can You Take PE-22-28 With Tirzepatide or Semaglutide?
Where PE-22-28 and a GLP-1 overlap
| Effect | On PE-22-28 | On tirzepatide or semaglutide | What to do |
|---|---|---|---|
| Tiredness | Not a described effect | Fatigue is a listed side effect | Start on different dates; report it if it persists |
| Headache | Occasional in the first days | Not a main point in Pepti's tirzepatide references | Report it if it persists |
| Nausea | Not a described effect | The most common side effect | Message your care team if it affects eating |
| Injection-site reactions | The commonest clinical report | 6 to 8% on tirzepatide against 2% | Rotate sites; do not inject both in the same spot |
| A marked change in mood | Not a described effect, always reportable | Not listed for tirzepatide; always reportable | Contact your physician promptly; 988 or 911 if you feel unsafe |
Starting both in the same week makes tiredness, headache and mood changes impossible to place. Starting one thing at a time is simpler.
Can You Take PE-22-28 With Tirzepatide or Semaglutide?
Psychiatric medication
PE-22-28's proposed mechanism overlaps with serotonin signalling. If you take an antidepressant, a triptan, lithium, tramadol or any other serotonergic drug, or have been diagnosed with major depression, bipolar disorder or psychosis, that treatment comes first, and any decision about PE-22-28 involves the clinician managing it. The combination has never been studied in people. Never stop or reduce a psychiatric medication to make room for PE-22-28 or to help a GLP-1 work.
Two more points connect the three. Several antidepressants and antipsychotics are described in reviews as promoting weight gain, which can be part of why weight is hard to shift. And a GLP-1 slows stomach emptying, which can change how quickly oral medications are absorbed in the first weeks after starting or increasing the dose. List every medication on your intake, and if another prescriber manages your mood, tell them you have started a GLP-1 and PE-22-28. An active eating disorder is a situation where a GLP-1 is usually avoided; say so on the intake if it applies.
Can You Take PE-22-28 With Tirzepatide or Semaglutide?
How the two schedules fit together
| PE-22-28 | Tirzepatide | |
|---|---|---|
| Draw | 0.25 mL (25 units) on a U-100 insulin syringe | 0.50 mL (50 units) at every strength |
| Per dose | 0.5 mg PE-22-28 (2 mg/mL vial) | Depends on the vial strength, 2.5 mg to 15 mg |
| When | Once daily, Monday through Friday | Once weekly |
| Doses per vial | 20, about four weeks | 4, four weeks |
| Refills | Every 28 days, one vial per fill | Every 28 days, one vial per fill |
The schedules are independent, and there is no described need to separate them by hours. Use a separate fresh syringe for each and never draw both into one. Dosing detail is in PE-22-28 dosage and tirzepatide dosing chart. Never change either dose yourself.
Can You Take PE-22-28 With Tirzepatide or Semaglutide?
What not to combine
| Combination | Why not |
|---|---|
| Tirzepatide with semaglutide or any other GLP-1 | Same receptor system, stacked side effects, no mechanism gained |
| PE-22-28 in place of a prescribed antidepressant | That treatment comes first; never stop it on your own |
| Two of your vials in one syringe | Neither label describes the mixture |
| Starting PE-22-28 in the same week as a GLP-1 dose increase | Tiredness and mood changes become impossible to place |
| Anything sold "for research use only" | Nobody is accountable for identity, purity, sterility or concentration |
Can You Take PE-22-28 With Tirzepatide or Semaglutide?
Semaglutide works the same way
Everything above applies to semaglutide. It acts at the GLP-1 receptor only, where tirzepatide acts at two, but its effects that can feel like low mood are the same kind: fatigue in the early weeks, dizziness, and low blood sugar with insulin or a sulfonylurea. Semaglutide and tirzepatide are never taken together. See semaglutide side effects.
Can You Take PE-22-28 With Tirzepatide or Semaglutide?
What the evidence shows, honestly
There are no human trials of PE-22-28 of any kind. Its evidence is cell and rodent work, mostly from one French research group, and the only human data in the area measures the body's own sortilin propeptide in blood. PE-22-28 has not been evaluated by the FDA at all: it is not in any category of the 503A nominated-substances list updated 14 May 2026 and was not on the July 2026 advisory committee agenda.
There is no study of PE-22-28 with a GLP-1. What can be said is that the two act on unrelated systems, no interaction is described, and the overlaps worth managing are early tiredness, injection-site reactions, mood changes that need reporting, and blood sugar for people on insulin or a sulfonylurea. The fuller pictures are in PE-22-28 side effects and tirzepatide side effects, and pairings in general are in what peptides can you take with tirzepatide.
Can You Take PE-22-28 With Tirzepatide or Semaglutide?
How to add PE-22-28 to a GLP-1 properly
- Report a mood change first. If it started with the GLP-1, your care team needs to know before anything is added.
- List every medication. Especially antidepressants, triptans, lithium, tramadol, insulin and sulfonylureas.
- Start one thing at a time. Begin PE-22-28 away from a GLP-1 dose increase.
- Report what happens, including nothing. Your care team is reachable through your account.
Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.
Can You Take PE-22-28 With Tirzepatide or Semaglutide?
Where to get PE-22-28 prescribed
- Complete a free online intake covering your history, including mental health history, diabetes, and every medication you take.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with ice packs, with sterile syringes and alcohol prep pads, and your directions printed on the vial.
- Your care team stays reachable for side effects and mood changes. Refills run every 28 days, one vial per fill.
Pepti is cash-pay and does not bill insurance. Step-by-step pages: how to get PE-22-28 prescribed online and how to get tirzepatide prescribed online.
References
What this is based on.
References
- Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) · New England Journal of Medicine (2021) · PMID 33567185
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) · New England Journal of Medicine (2023) · PMID 37952131
- Wadden TA, Bailey TS, Billings LK, et al.. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3) · JAMA (2021) · PMID 33625476
- Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial · JAMA (2021) · PMID 33755728
- Marso SP, Bain SC, Consoli A, et al.. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) · New England Journal of Medicine (2016) · PMID 27633186
- Davies M, Færch L, Jeppesen OK, et al.. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial · The Lancet (2021) · PMID 33667417
- Garvey WT, Batterham RL, Bhatta M, et al.. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial · Nature Medicine (2022) · PMID 36216945
- Rubino DM, Greenway FL, Khalid U, et al.. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial · JAMA (2022) · PMID 35015037
- Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) · New England Journal of Medicine (2025) · PMID 40353578
- Sanyal AJ, Newsome PN, Kliers I, et al.. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE) · New England Journal of Medicine (2025) · PMID 40305708
- Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension · Diabetes Obes Metab (2022) · PMID 35441470
- Batsis JA, Gavras A, Gross DC, Cheever CR, Da Silva BR et al.. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review · Ann Intern Med (2026) · PMID 41996180
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
Can You Take PE-22-28 With Tirzepatide or Semaglutide?, answered.
Yes, a physician can prescribe both after reviewing your intake. They act on unrelated systems and no interaction is described, but the combination has not been studied, and PE-22-28 has no human trials.
The answer is the same as for tirzepatide, including ruling out GLP-1 side effects that feel like low mood and watching blood sugar if you take insulin or a sulfonylurea.
No study has tested that, and PE-22-28 has never been tested for mood in people. Fatigue, dizziness and low blood sugar on a GLP-1 can feel like low mood, so report the change to your care team first.
Cell work described its parent peptide increasing insulin secretion from pancreatic beta cells. It has not been measured in people. If you have diabetes, or take insulin or a sulfonylurea with a GLP-1, raise it on your intake.
It is not described as acting on appetite and has not been studied for weight.
Your antidepressant comes first and should never be stopped or reduced on your own. PE-22-28 has never been studied with antidepressants, so the prescribers of all three need to know.
The schedules are independent, and there is no described need to separate them by hours. Use a separate syringe for each, never mix them, and follow the directions printed on each vial.
Fatigue is a listed tirzepatide side effect, often linked to eating and drinking less. It is not a described PE-22-28 effect. Report tiredness that does not settle.
Contact your physician promptly. If you have thoughts of harming yourself, call or text 988 in the US, or call 911, now.
No. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.

